DiscoveryProbe™ FDA-approved Drug Library: Enabling High-Throughput Screening and Pharmacological Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) provides 2,320 compounds that have been approved by major regulatory agencies, supporting rapid drug repositioning and mechanistic discovery (product page). These compounds represent a wide spectrum of mechanisms, including receptor modulation and enzyme inhibition. The resource is pre-dissolved in 10 mM DMSO, facilitating integration into HTS and HCS workflows. Stability data confirm 12–24 month shelf-life under standard storage conditions. The library has been leveraged in clinically relevant screens, as demonstrated in recent pain pathway research (Ullrich et al., 2023).

Biological Rationale

High-throughput screening (HTS) and high-content screening (HCS) are essential tools for the discovery of new therapeutic agents and for drug repositioning. The use of FDA-approved bioactive compound libraries provides the advantage of known safety and pharmacokinetic profiles (DiscoveryProbe™ FDA-approved Drug Library). Such libraries enable mechanistic studies across diverse disease models, including oncology, neurodegeneration, and infectious diseases (internal link; this article extends previous coverage by focusing on benchmarked screening outcomes and practical workflow integration). The compounds within the DiscoveryProbe™ FDA-approved Drug Library have been selected based on clinical approval records from the FDA, EMA, HMA, CFDA, and PMDA, or inclusion in established pharmacopeias, ensuring regulatory-grade quality and traceability.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library comprises compounds with diverse, well-characterized mechanisms of action. Key categories include:

• Receptor agonists and antagonists: Targeting GPCRs, nuclear hormone receptors, and neurotransmitter systems (e.g., serotonin 5-HT1A receptor agonists such as befiradol, which modulate pain and mood pathways; Ullrich et al., 2023).
• Enzyme inhibitors: Including kinase inhibitors, protease inhibitors, and metabolic enzyme modulators (e.g., metformin targets AMPK-related pathways, while statins inhibit HMG-CoA reductase).
• Ion channel modulators: Agents affecting sodium, potassium, calcium, and chloride channels, relevant for neurodegenerative and cardiovascular diseases.
• Signal pathway regulators: Compounds modulating MAPK, PI3K/AKT, and other key signaling cascades.

Each compound’s mechanism is supported by regulatory documentation and peer-reviewed literature, enabling target-based and phenotypic screens.

Evidence & Benchmarks

• The DiscoveryProbe™ FDA-approved Drug Library contains exactly 2,320 distinct bioactive compounds, each traceable to clinical approval or pharmacopeial listing (Product Data Sheet).
• Compounds are provided as 10 mM solutions in DMSO, with validated stability for 12 months at -20°C and 24 months at -80°C (Product Data Sheet).
• High-throughput screening using FDA-approved drug libraries enabled the identification of novel GPCR ligands, such as ST171 for the 5-HT1A receptor, with an EC50 of 0.3 nM (in vitro Gi activation; Ullrich et al., 2023).
• Screening of similar FDA-approved drug libraries has been used to identify compounds that modulate critical disease pathways, such as ChaC1-mediated oxidative stress in cancer (internal link; this article updates mechanistic models with recent screening data).
• Compared to custom synthesis, use of regulatory-grade drug libraries reduces screening cycle time and ensures direct translational relevance (internal link; here, we further detail stability and storage parameters for HTS labs).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports a variety of research applications:

• Drug repositioning screening: Enables discovery of new indications for approved drugs.
• Pharmacological target identification: Facilitates mechanistic studies in disease models.
• Cancer research drug screening: Allows rapid identification of compounds affecting tumor signaling pathways.
• Neurodegenerative disease drug discovery: Supports screens for modulators of neuronal survival and function.
• Signal pathway regulation and enzyme inhibitor screening: Enables systematic mapping of pathway vulnerabilities.

Common Pitfalls or Misconceptions

• The library does not include investigational or preclinical compounds lacking regulatory approval.
• Screening results are context-dependent; hits require secondary validation in relevant biological systems.
• Compound potency and bioavailability in vitro may not predict clinical efficacy due to formulation or metabolism differences.
• Not all disease mechanisms are covered; rare or ultra-novel targets may not be represented.
• HTS artifacts (e.g., DMSO sensitivity, aggregation) must be controlled for in assay setup.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is optimized for integration into automated screening platforms. Key workflow features and parameters include:

• Format: Supplied in 96-well or deep-well plates, as well as 2D barcoded screw-top tubes, compatible with most liquid handling systems.
• Concentration: 10 mM solutions in DMSO (v/v), ready for dilution into assay buffers.
• Storage: Stable for 12 months at -20°C and 24 months at -80°C; shipping on blue ice for evaluation sizes and room temperature or blue ice for bulk orders.
• Automation readout: Suitable for HTS/HCS platforms and endpoint or kinetic assays.
• Compound identity tracking: Each well is barcoded; electronic records ensure traceability.

For detailed methodology and strategic guidance, see this internal article, which our current article extends by providing updated evidence on pain pathway and immuno-oncology screening successes.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) provides a robust, validated platform for HTS, HCS, and translational pharmacology. Its regulatory-grade curation and format flexibility accelerate both drug repositioning and novel target discovery. Recent advances in GPCR, kinase, and cancer pathway screening illustrate its value in identifying clinically actionable hits. Ongoing integration with mechanistic and phenotypic screening platforms is expected to further enhance its utility in precision medicine research. For product details, visit the DiscoveryProbe™ FDA-approved Drug Library homepage.